🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to researchers.

An International Public Health Issue

The sexually transmitted infection are on the rise worldwide, with data suggesting over 82 million instances each year. Notably increased rates are seen in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, the spread of superbugs and the extremely scarce treatment choices at this time.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has classified it as a "critical concern". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in December for use against gonorrhoea. This infection can lead to major issues, including infertility. Researchers anticipate that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This medication, which is also used to treat UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This approval marks a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Clinical Trial Results and Global Access

According to findings released by a major medical journal, zoliflodacin successfully treated more than 90% of cases of the STI. This places it at an equal footing with the existing first-line therapy, which combines a dual-drug approach. The research involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to make available and distribute the drug in many developing nations.

Clinicians on the front lines have voiced positive views. Having a single-dose, oral treatment like this is hailed as a "game-changer" for gonorrhoea control. This is considered crucial to alleviate the strain of the illness for individuals and to stop the proliferation of untreatable gonorrhoea globally.